drugset / Trial / NCT04260256
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
Phase 2
Terminated
9 enrolled
CellSight Technologies, Inc.
Oregon Health and Science University · collabStanford University · collab
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
In this study, patients with advanced solid tumors will undergo \[18F\]F AraG PET/CT imaging to assess for changes in tracer uptake following treatment with CkIT.
Timeline
- Start
- 2022-03-01
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
Outcome
Outcome not reported
Stopped (Business): “lack of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F-ARAG | Diagnostic / imaging agent | — | — |